Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1178063rdf:typepubmed:Citationlld:pubmed
pubmed-article:1178063lifeskim:mentionsumls-concept:C0026845lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0028351lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C1522565lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0034783lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0022245lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0001272lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:1178063lifeskim:mentionsumls-concept:C2926735lld:lifeskim
pubmed-article:1178063pubmed:issue4lld:pubmed
pubmed-article:1178063pubmed:dateCreated1976-1-2lld:pubmed
pubmed-article:1178063pubmed:abstractText1. On guinea-pig papillary muscle we investigated whether a prolonging effect of noradrenaline on the duration of the cardiac ventricular action potential (AP) is attributable to an action on beta-adrenoceptors. 2. Propranolol (5 X 10(-6) M), which itself shortens AP (at 90% repolarization level), inhibits both effects of noradrenaline on the AP, i.e. the sustained prolongation by low concentrations (10(-7)--10(-6)M) and the steady-state shortening which follows an initial prolongation by a high concentration (10(-5)M). In the presence of propranolol, the prlonging effect of noradrenaline is shifted to higher concentrations (10(-6)--10(-5)M). This prolongation of AP duration does not exceed the prior shortening effect by propranolol; it is not prevented by 10(-5)M phentolamine. 3. Phentolamine, which itself prolongs AP duration, inhibits neither the initial prolongation nor the steady-state shortening of the AP by 10(-5)M noradrenaline. Instead, the biphasic change in AP duration as well as the positive inotropic effect of 10(-5)M noradrenaline are enhanced in the presence of 3Z10(-6)M phentolamine. 4. The effect of isoprenaline on the duration of AP qualitatively resembles that of noradrenaline. In a concentration of 10(-8)M, isoprenaline produces a sustained prolongation of the AP; concentrations of 10(-7)M and 10(-6)M cause an initial prolongation which is followed by a steady-state shortening. These effects are inhibited by propranolol. 5. It is concluded that not only the steady-state shortening effect on AP duration by 10(-5)M noradrenaline but also the prolongation of AP, induced by lower noradrenaline concentrations (10(-7)--10(-6)M), are mediated solely by an action on beta-adrenoceptors.lld:pubmed
pubmed-article:1178063pubmed:languageenglld:pubmed
pubmed-article:1178063pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:citationSubsetIMlld:pubmed
pubmed-article:1178063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1178063pubmed:statusMEDLINElld:pubmed
pubmed-article:1178063pubmed:issn0028-1298lld:pubmed
pubmed-article:1178063pubmed:authorpubmed-author:ReiterMMlld:pubmed
pubmed-article:1178063pubmed:authorpubmed-author:QuadbeckJJlld:pubmed
pubmed-article:1178063pubmed:issnTypePrintlld:pubmed
pubmed-article:1178063pubmed:volume288lld:pubmed
pubmed-article:1178063pubmed:ownerNLMlld:pubmed
pubmed-article:1178063pubmed:authorsCompleteYlld:pubmed
pubmed-article:1178063pubmed:pagination403-14lld:pubmed
pubmed-article:1178063pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:meshHeadingpubmed-meshheading:1178063-...lld:pubmed
pubmed-article:1178063pubmed:year1975lld:pubmed
pubmed-article:1178063pubmed:articleTitleAdrenoceptors in cardiac ventricular muscle and changes in duration of action potential caused by noradrenaline and isoprenaline.lld:pubmed
pubmed-article:1178063pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1178063pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1178063lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1178063lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1178063lld:pubmed